{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:22:25Z","timestamp":1790666545937,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03949-w","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T06:53:17Z","timestamp":1768632797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Shuang","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujian","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5788-8373","authenticated-orcid":false,"given":"Hang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"3949_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"3949_CR2","doi-asserted-by":"publisher","first-page":"e70410","DOI":"10.1002\/cam4.70410","volume":"13","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zou Y, Ye Y, Chen Y (2024) Advances in the Understanding of the pathogenesis of Triple-Negative breast cancer. Cancer Med 13:e70410. https:\/\/doi.org\/10.1002\/cam4.70410","journal-title":"Cancer Med"},{"key":"3949_CR3","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"AM Karim","year":"2023","unstructured":"Karim AM, Eun Kwon J, Ali T et al (2023) Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol 212:115545. https:\/\/doi.org\/10.1016\/j.bcp.2023.115545","journal-title":"Biochem Pharmacol"},{"key":"3949_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","volume":"147","author":"X Zhang","year":"2023","unstructured":"Zhang X (2023) Molecular classification of breast cancer: relevance and challenges. Arch Pathol Lab Med 147:46\u201351. https:\/\/doi.org\/10.5858\/arpa.2022-0070-RA","journal-title":"Arch Pathol Lab Med"},{"key":"3949_CR5","doi-asserted-by":"publisher","unstructured":"Prat A, Pineda E, Adamo B et al (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24 Suppl 2S26\u201335. https:\/\/doi.org\/10.1016\/j.breast.2015.07.008","DOI":"10.1016\/j.breast.2015.07.008"},{"key":"3949_CR6","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.2217\/fon-2018-0131","volume":"14","author":"N Tray","year":"2018","unstructured":"Tray N, Adams S, Esteva FJ (2018) Antibody\u2013drug conjugates in triple negative breast cancer. Future Oncol 14:2651\u20132661. https:\/\/doi.org\/10.2217\/fon-2018-0131","journal-title":"Future Oncol"},{"key":"3949_CR7","unstructured":"National Comprehensive Cancer Network - Home In: NCCN. https:\/\/www.nccn.org. Accessed 22 May 2025"},{"key":"3949_CR8","unstructured":"ESMO Living Guideline (2025) \u200bMetastatic Breast Cancer | ESMO. https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-metastatic-breast-cancer. Accessed 22 May"},{"key":"3949_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM et al (2021) Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529\u20131541. https:\/\/doi.org\/10.1056\/NEJMoa2028485","journal-title":"N Engl J Med"},{"key":"3949_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10549-022-06602-7","volume":"195","author":"J O\u2019Shaughnessy","year":"2022","unstructured":"O\u2019Shaughnessy J, Brufsky A, Rugo HS et al (2022) Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab Govitecan in metastatic triple-negative breast cancer. Breast Cancer Res Treat 195:127\u2013139. https:\/\/doi.org\/10.1007\/s10549-022-06602-7","journal-title":"Breast Cancer Res Treat"},{"key":"3949_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Tolaney SM, Loirat D et al (2022) Sacituzumab Govitecan in metastatic Triple-Negative breast cancer. NPJ Breast Cancer 8:98. https:\/\/doi.org\/10.1038\/s41523-022-00467-1","journal-title":"NPJ Breast Cancer"},{"key":"3949_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41523-022-00439-5","volume":"8","author":"LA Carey","year":"2022","unstructured":"Carey LA, Loirat D, Punie K et al (2022) Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. NPJ Breast Cancer 8:72. https:\/\/doi.org\/10.1038\/s41523-022-00439-5","journal-title":"NPJ Breast Cancer"},{"key":"3949_CR13","doi-asserted-by":"publisher","first-page":"01409","DOI":"10.1200\/JCO.23.01409","volume":"23","author":"A Bardia","year":"2024","unstructured":"Bardia A, Rugo HS, Tolaney SM et al (2024) Final results from the randomized phase III ASCENT clinical trial in metastatic Triple-Negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol JCO 23:01409. https:\/\/doi.org\/10.1200\/JCO.23.01409","journal-title":"J Clin Oncol JCO"},{"key":"3949_CR14","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1002\/cam4.4052","volume":"10","author":"W-Q Li","year":"2021","unstructured":"Li W-Q, Guo H-F, Li L-Y et al (2021) The promising role of antibody drug conjugate in cancer therapy: combining targeting ability with cytotoxicity effectively. Cancer Med 10:4677\u20134696. https:\/\/doi.org\/10.1002\/cam4.4052","journal-title":"Cancer Med"},{"key":"3949_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z (2018) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33\u201346. https:\/\/doi.org\/10.1007\/s13238-016-0323-0","journal-title":"Protein Cell"},{"key":"3949_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, Li M, Li Y et al (2024) A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers. Mol Cancer 23:62. https:\/\/doi.org\/10.1186\/s12943-024-01963-7","journal-title":"Mol Cancer"},{"key":"3949_CR17","first-page":"1671","volume":"12","author":"P Jabbarzadeh Kaboli","year":"2022","unstructured":"Jabbarzadeh Kaboli P, Shabani S, Sharma S et al (2022) Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res 12:1671\u20131685","journal-title":"Am J Cancer Res"},{"key":"3949_CR18","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","volume":"35","author":"A Bardia","year":"2017","unstructured":"Bardia A, Mayer IA, Diamond JR et al (2017) Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol 35:2141\u20132148. https:\/\/doi.org\/10.1200\/JCO.2016.70.8297","journal-title":"J Clin Oncol"},{"key":"3949_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA et al (2021) Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol 32:746\u2013756. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.005","journal-title":"Ann Oncol"},{"key":"3949_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT et al (2019) Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med 380:741\u2013751. https:\/\/doi.org\/10.1056\/NEJMoa1814213","journal-title":"N Engl J Med"},{"key":"3949_CR21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"3949_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D et al (2003) Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg 73:712\u2013716. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x","journal-title":"ANZ J Surg"},{"key":"3949_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"3949_CR24","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ijc.34424","volume":"152","author":"B Xu","year":"2023","unstructured":"Xu B, Ma F, Wang T et al (2023) A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. Int J Cancer 152:2134\u20132144. https:\/\/doi.org\/10.1002\/ijc.34424","journal-title":"Int J Cancer"},{"key":"3949_CR25","doi-asserted-by":"publisher","unstructured":"Naito Y, Nakamura S, Kawaguchi-Sakita N et al (2024) Preliminary results from ASCENT-J02: a phase 1\/2 study of sacituzumab Govitecan in Japanese patients with advanced solid tumors. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-024-02589-x","DOI":"10.1007\/s10147-024-02589-x"},{"key":"3949_CR26","doi-asserted-by":"publisher","first-page":"175883592312004","DOI":"10.1177\/17588359231200454","volume":"15","author":"M Reinisch","year":"2023","unstructured":"Reinisch M, Bruzas S, Spoenlein J et al (2023) Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany. Ther Adv Med Oncol 15:17588359231200454. https:\/\/doi.org\/10.1177\/17588359231200454","journal-title":"Ther Adv Med Oncol"},{"key":"3949_CR27","doi-asserted-by":"publisher","first-page":"1362641","DOI":"10.3389\/fonc.2024.1362641","volume":"14","author":"R Caputo","year":"2024","unstructured":"Caputo R, Buono G, Piezzo M et al (2024) Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis. Front Oncol 14:1362641. https:\/\/doi.org\/10.3389\/fonc.2024.1362641","journal-title":"Front Oncol"},{"key":"3949_CR28","doi-asserted-by":"publisher","unstructured":"De Moura A, Loirat D, Vaillant S et al (2024) Sacituzumab Govitecan in metastatic triple-negative breast cancer patients treated at Institut curie hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. https:\/\/doi.org\/10.1007\/s12282-024-01565-7","DOI":"10.1007\/s12282-024-01565-7"},{"key":"3949_CR29","doi-asserted-by":"publisher","unstructured":"Kalinsky K, Spring L, Yam C et al (2024) Real-world use patterns, effectiveness, and tolerability of sacituzumab Govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the united States. Breast Cancer Res Treat. https:\/\/doi.org\/10.1007\/s10549-024-07412-9","DOI":"10.1007\/s10549-024-07412-9"},{"key":"3949_CR30","doi-asserted-by":"publisher","unstructured":"Hanna D, Merrick S, Ghose A et al (2024) Real world study of sacituzumab Govitecan in metastatic triple-negative breast cancer in the United Kingdom. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-024-02685-9","DOI":"10.1038\/s41416-024-02685-9"},{"key":"3949_CR31","doi-asserted-by":"publisher","unstructured":"P\u00fcsk\u00fcll\u00fco\u011flu M, Pieni\u0105\u017cek M, Las-Jankowska M et al (2024) Sacituzumab Govitecan for second and subsequent line palliative treatment of patients with Triple-Negative breast cancer: A Polish Real-World multicenter cohort study. Oncol Ther.\u00a0https:\/\/doi.org\/10.1007\/s40487-024-00307-1","DOI":"10.1007\/s40487-024-00307-1"},{"key":"3949_CR32","doi-asserted-by":"publisher","first-page":"00242","DOI":"10.1200\/OP.24.00242","volume":"24","author":"S Alaklabi","year":"2024","unstructured":"Alaklabi S, Roy AM, Zagami P et al (2024) Real-World clinical outcomes with sacituzumab Govitecan in metastatic Triple-Negative breast cancer. JCO Oncol Pract OP 24:00242. https:\/\/doi.org\/10.1200\/OP.24.00242","journal-title":"JCO Oncol Pract OP"},{"key":"3949_CR33","doi-asserted-by":"publisher","unstructured":"Carri\u00f3n-Madro\u00f1al IM, D\u00edaz-Acedo R, Lora-Escobar SJ et al (2024) Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study. Future Oncol 1\u20139. https:\/\/doi.org\/10.1080\/14796694.2024.2394408","DOI":"10.1080\/14796694.2024.2394408"},{"key":"3949_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1055\/a-2375-5194","volume":"84","author":"H Sch\u00e4ffler","year":"2024","unstructured":"Sch\u00e4ffler H, Jakob D, Huesmann S et al (2024) Novel antibody-drug-conjugates in routine clinical practice for the treatment of metastatic breast cancer: adherence, efficacy and tolerability - real-world data from German breast centers. Geburtshilfe Frauenheilkd 84:855\u2013865. https:\/\/doi.org\/10.1055\/a-2375-5194","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"3949_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Tolaney SM, Loirat D et al (2022) Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer 8:98. https:\/\/doi.org\/10.1038\/s41523-022-00467-1","journal-title":"NPJ Breast Cancer"},{"key":"3949_CR36","doi-asserted-by":"crossref","unstructured":"Yang L, Duan X, Wu S et al (2024) Mining and influencing factors analysis of sacituzumab Govitecan adverse drug event based on FAERS database. Expert Opin Drug Saf","DOI":"10.1080\/14740338.2024.2430305"},{"key":"3949_CR37","doi-asserted-by":"publisher","unstructured":"Sathe AG, Diderichsen PM, Fauchet F et al (2024) Exposure\u2013Response analyses of sacituzumab Govitecan efficacy and safety in patients with metastatic Triple-Negative breast cancer. Clinical Pharmacology & Therapeutics. https:\/\/doi.org\/10.1002\/cpt.3495","DOI":"10.1002\/cpt.3495"},{"key":"3949_CR38","doi-asserted-by":"publisher","unstructured":"(2022) Sacituzumab Govitecan in metastatic triple negative breast cancer (TNBC): four design features in the ASCENT trial potentially favored the experimental arm. Translational Oncol 15:101248. https:\/\/doi.org\/10.1016\/j.tranon.2021.101248","DOI":"10.1016\/j.tranon.2021.101248"},{"key":"3949_CR39","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.3390\/cancers16213622","volume":"16","author":"M P\u00e9rez-Bermejo","year":"2024","unstructured":"P\u00e9rez-Bermejo M, Caballero-Pascual M, Legidos-Garc\u00eda ME et al (2024) Sacituzumab govitecan in triple negative breast cancer: a systematic review of clinical trials. Cancers 16:3622. https:\/\/doi.org\/10.3390\/cancers16213622","journal-title":"Cancers"},{"key":"3949_CR40","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","volume":"19","author":"R Largillier","year":"2008","unstructured":"Largillier R, Ferrero J-M, Doyen J et al (2008) Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 19:2012\u20132019. https:\/\/doi.org\/10.1093\/annonc\/mdn424","journal-title":"Ann Oncol"},{"key":"3949_CR41","doi-asserted-by":"publisher","first-page":"e746","DOI":"10.1634\/theoncologist.2019-0647","volume":"25","author":"M Di Maio","year":"2020","unstructured":"Di Maio M, Perrone F, Conte P (2020) Real-world evidence in oncology: opportunities and limitations. Oncologist 25:e746\u2013e752. https:\/\/doi.org\/10.1634\/theoncologist.2019-0647","journal-title":"Oncologist"},{"key":"3949_CR42","unstructured":"Influencia de los polimorfismos del gen UGT1A1 en el tratamiento con sacituzumab govitecan Revisi\u00f3n narrativa - ScienceDirect. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1130634325000169?via%3Dihub. Accessed 26 May 2025"},{"key":"3949_CR43","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3892\/ol.2011.533","volume":"3","author":"K Hirose","year":"2012","unstructured":"Hirose K, Kozu C, Yamashita K et al (2012) Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene. Oncol Lett 3:694\u2013698. https:\/\/doi.org\/10.3892\/ol.2011.533","journal-title":"Oncol Lett"},{"key":"3949_CR44","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/fcp.12117","volume":"29","author":"M-C Etienne-Grimaldi","year":"2015","unstructured":"Etienne-Grimaldi M-C, Boyer J-C, Thomas F et al (2015) UGT1A1 genotype and Irinotecan therapy: general review and implementation in routine practice. Fundam Clin Pharmacol 29:219\u2013237. https:\/\/doi.org\/10.1111\/fcp.12117","journal-title":"Fundam Clin Pharmacol"},{"key":"3949_CR45","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1111\/j.1349-7006.2007.00541.x","volume":"98","author":"SR Jada","year":"2007","unstructured":"Jada SR, Lim R, Wong CI et al (2007) Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C\u2009>\u2009A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98:1461\u20131467. https:\/\/doi.org\/10.1111\/j.1349-7006.2007.00541.x","journal-title":"Cancer Sci"},{"key":"3949_CR46","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/j.1349-7006.2006.00321.x","volume":"97","author":"K Araki","year":"2006","unstructured":"Araki K, Fujita K, Ando Y et al (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255\u20131259. https:\/\/doi.org\/10.1111\/j.1349-7006.2006.00321.x","journal-title":"Cancer Sci"},{"key":"3949_CR47","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2005.03.0239","volume":"24","author":"J-Y Han","year":"2006","unstructured":"Han J-Y, Lim H-S, Shin ES et al (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non\u2013small-cell lung cancer treated with irinotecan and cisplatin. JCO 24:2237\u20132244. https:\/\/doi.org\/10.1200\/JCO.2005.03.0239","journal-title":"JCO"},{"key":"3949_CR48","doi-asserted-by":"publisher","unstructured":"Peng H, Duan Z, Pan D et al (2017) UGT1A1 gene polymorphism predicts Irinotecan-Induced severe neutropenia and diarrhea in Chinese cancer patients. Clin Lab 63. https:\/\/doi.org\/10.7754\/Clin.Lab.2017.170105","DOI":"10.7754\/Clin.Lab.2017.170105"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03949-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03949-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03949-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:03:47Z","timestamp":1771859027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03949-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3949"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03949-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}